Prostatic neuroendocrine cells (NE) are an integral part of prostate cancer (PCa) and are associated with PCa progression. As the current androgen deprivation therapy with anti-androgens may promote the neuroendocrine PCa (NEPCa) development, and few therapies can effectively suppress NEPCa, understanding the impact of NEPCa on PCa progression may help us to develop better therapies to battle PCa. Here, we found NEPCa cells could increase the docetaxel resistance of their neighboring PCa cells. Mechanism dissection revealed that through secretion of PTHrP, NEPCa cells could alter the p38/MAPK/Hsp27 signals in their neighboring PCa cells that resulted in increased androgen receptor (AR) activity via promoting AR nuclear translocation. The consequences of increased AR function might then increase docetaxel resistance via increasing p21 expression. In vivo xenograft mice experiments also confirmed that NEPCa could increase the docetaxel resistance of neighboring PCa, and targeting this newly identified PTHrP/p38/Hsp27/AR/p21 signaling pathway with either p38 inhibitor (SB203580) or shPTHrP may result in improving/restoring the docetaxel sensitivity to better suppress PCa.
INTRODUCTION
Prostate cancer (PCa) is one of the most commonly diagnosed tumors in men in western countries. 1 Although androgen deprivation therapy (ADT) is effective for some patients, most patients may develop castration resistance with the development of metastatic PCa.
2 Docetaxel (Doc) has been used as a standard treatment for these patients with castration-resistant PCa (CRPC). 3 However, the therapeutic durability for Doc is limited (average 18 months) with some serious side effects. 4, 5 Neuroendocrine prostate cancer (NEPCa) represents a minor population of PCa, yet NEPCa cells exist in the most advanced stages of PCa. 6 Importantly, the population of NEPCa cells might increase during the current ADT with anti-androgen treatments. 7 Different from most PCa cells, NEPCa cells express little androgen receptor (AR); thus, they are inherently resistant to the ADT treatment. The common markers for these NEPCa cells are Chromogranin, neuron-specific enolase and synaptophysin. 8 Early studies suggested that NEPCa cells might secrete various factors, including bombesin, parathyroid hormone-related protein (PTHrP), adrenomedullin and vascular endothelial growth factor to influence the surrounding PCa progression. [9] [10] [11] However, the detailed mechanisms, especially their influences on the AR, the key factor for the PCa progression, as well as their impact on the efficacy of chemotherapies such as Doc, remain unclear.
In an in vitro system of co-culturing cells and in vivo mouse xenograft studies, we demonstrated that NEPCa could increase the chemoresistance of neighboring PCa via altering the p38/ Hsp27/AR/p21 signals.
RESULTS

NEPCa increased chemoresistance of neighboring PCa
Early studies suggested that NEPCa is not only resistant to existing therapies in general, its conditioned media (CM) might also enhance the development of castration resistance in its neighboring PCa (CRPC). 12, 13 To further study the impact of NEPCa cells on the chemosensitivity on the neighboring PCa cells, we determined the efficacy of Doc on PCa cells before and after their co-culture with the NEPCa cells ( Figure 1a ). We found that after co-culture with the NEPCa NCI-H660 cells, CRPC C4-2 cells become more resistant to Doc treatment in a dose-dependent manner ranging from 1 nM to 8 nM (Figure 1b , left panel) and the viability of these C4-2 cells are increased as gauged by MTT assay. Similar results were also obtained when we replaced C4-2 with CWR22Rv1 cells (Figure 1b , right panel).
To determine that the viability of these CRPC cells are related to programmed cell death, we applied the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay to examine the impact of co-culturing with NEPCa; the results indicated that NCI-H660 cells might protect C4-2 and CWR22Rv1 cells from Docinduced apoptosis (Figure 1c) . Meanwhile, co-culture with NCI-H660 cells also decreased the level of cleaved PARP, another indicator for the apoptotic process 14 ( Figure 1d ). Importantly, similar results were also obtained when we replaced the NCI-H660 cells with NE1.3 cells, which are LNCaP cells cultured long-term in the absence of androgen 15 and have the characteristics of NEPCa cells (Figures 1e and f) .
Together, results from Figure 1 suggest that NEPCa may confer a survival advantage to the surrounding PCa through enhancing their resistance to chemotherapy.
NEPCa-induced chemoresistance of surrounding PCa via altering the p38/Hsp27 signals To dissect the molecular mechanisms how NEPCa increased chemoresistance of surrounding PCa, we first screened commonly known signals related to apoptosis and proliferation. We found that p42/44/MAPK and p38/MAPK signals could be activated (via phosphorylation) by NEPCa (Figure 2a ). Increasing evidences suggest that p38/MAPK signals may have a crucial role in regulating tumor apoptosis and activation of the p38 kinase has been shown to be essential for tumor survival in response to select NEPCa activated p38/MAPK/Hsp27 pathway and p38/MAPK inhibitor can partially reverse NEPCa-induced chemoresistance. C4-2 and CWR22Rv1 cells were cultured with or without NE1.3 cells for 72 h in 6-well plates and the CM was collected. (a) p44/42 and p38 were phosphoactivated by NEPCa. C4-2 and CWR22Rv1 cells were starved with SR media for 24 h, then treated with CM. Total proteins were analyzed by western blotting as shown using anti-phospho-p42/44 and anti-phospho-p38 antibodies. (b, c) The p38 inhibitor SB203580 (10 μmol/l) can partially reverse NEPCa-induced chemoresistance of PCa. We treated C4-2/CWR22Rv1 cells with or without SB203580 for 15 min and subsequently treated with coculture CM or control media for an additional 24 h. After that, pre-treated cells were treated with or without 3 nM Doc for 48 h. TUNEL assay analysis (b) of cell apoptosis and western blot analysis (c) of the expression of cleaved PARP. The right panels are the quantitative data for TUNEL and western blot. (d) PCa/NEPCa co-culture CM phosphorylates p38 and Hsp27 in a time-dependent manner. C4-2 and CWR22Rv1 cells were starved with SR media for 24 h, then treated with PCa/NEPCa co-culture CM for different times (5, 15, or 30 min and 1 h). Total proteins were analyzed by western blotting as shown using anti-phospho-p38 and anti-phospho-Hsp27 antibodies. Anti-total p38 was used for control loading. (e) Activation of p38 is required for NEPCa-induced phosphorylation of Hsp27. We treated C4-2 and CWR22Rv1 cells with or without SB203580 for 15 min and subsequently treated with PCa/NEPCa co-culture CM for different times (0, 10 and 20 min). Western blot analysis of the expression of phosphorylated Hsp27. *Po0.05, and ns, no statistical differences. chemotherapeutic cancer drugs. [16] [17] [18] Moreover, pre-incubation of C4-2/CWR22Rv1 cells with 10 μM SB203580, a p38 kinase inhibitor, abolished the NEPCa capacity to increase the chemoresistance in the neighboring PCa (Figures 2b and c) . Therefore, we focused on the p38/MAPK pathway, and determined its activation through measuring the phosphorylation of p38 (Thr180/Tyr182) with phospho-specific antibodies on a western blot. p38 phosphorylation was increased in a time-dependent manner, with a maximum stimulation at 15 min after treatment with NE1.3 conditioned media (CM) (Figure 2d) . A similar activation can also be detected with NCI-H660 CM (Figure 2d ). These results suggest that NEPCa may increase the surrounding PCa chemoresistance via altering the p38/MAPK signals.
Among many substrates of p38/MAPK, Heat shock protein 27 (Hsp27), as a chaperone of the small heat shock protein group, can be activated through phosphorylation in response to cell stress to prevent apoptosis and to regulate cell differentiation. 19, 20 Upregulation of Hsp27 has been associated with chemoresistance and radiation resistance. 21, 22 p38 kinase can phosphorylate Hsp27 at multiple serines, including Ser15, Ser78 and Ser82. 23 Therefore, we detected the phosphorylation of Hsp27 (Ser78) through phospho-specific antibody and found that CM from NEPCa could rapidly induce phosphorylation of Hsp27 (Ser78) in a time-dependent manner (Figure 2d ). Importantly, addition of 10 μM SB203580 inhibited the NE1.3-induced Hsp27 phosphorylation in neighboring PCa, suggesting that activation of p38 is required for NEPCa-increased phosphorylation of Hsp27 (Figure 2e) .
Together, results from Figure 2 indicated that NEPCa increased the neighboring PCa chemoresistance likely via the p38/Hsp27 signals. Androgen receptor in the PCa chemoresistance induced by NEPCa It is well documented that activation of AR is related to progression of PCa, 24 and it has an important role as a survival factor in prostate epithelial cells. 25 Activation of AR by androgen enhances LNCaP cell survival in the presence of cytotoxic stress. 26 More recently, Zoubeidi et al. 27 found that non-nuclear phosphoHsp27 might displace Hsp90 in the AR complex to chaperone AR into the nucleus with consequent increase of AR activity. We therefore examined whether NEPCa-increased p38-Hsp27 signals may also link to the activation of AR.
We first detected AR expression at the protein level in the PCa cells after co-culture with NEPCa cells. We found little change of AR expression in C4-2 and CWR22Rv1 cells after co-culture with NE1.3 cells (Supplementary Figure S1) . However, the transcript levels of AR-target genes such as PSA, TMPRSS2 and FKBP5, as detected by quantitative real-time PCR, was increased upon co-culture with NE1.3 cells (Figure 3a ) and NCI-H660 cells (Supplementary Figure S2) . In addition, androgen response element-luciferase reporter assay further substantiated the activation of AR (Figure 3b ). Moreover, pre-incubation of C4-2/ CWR22Rv1 cells with p38 kinase inhibitor could partially abolish the NEPCa capacity to increase the AR activity in the neighboring PCa ( Figure 3c ). Consistent with the increased AR activity, staining with fluorescently labeled anti-AR antibody also confirmed that NEPCa CM could increase AR nuclear translocation (from the cytoplasm) in C4-2 cells (Figure 3d , left panel). In addition, expression of exogenous AR in AR-negative PCa DU145 cells also demonstrated its nuclear localization in response to NEPCa CM ( Figure 3d , right panel).
Importantly, the stably AR overexpressed PC3 cells, PC3-AR9, also revealed more resistance to Doc after co-culturing with NE1.3 cells compared with the parental PC3 cells (Figure 3e ).
Together, results from Figure 3 suggest that NEPC may increase the neighboring PCa chemoresistance via increased p38/Hsp27 signals that likely result in increased AR activity via enhanced AR nuclear translocation.
Mechanism dissection how NEPCa-increased p38/Hsp27/AR signals enhance neighboring PCa chemoresistance Previously, Lu et al. 28 found that androgen upregulated the cyclindependent kinase inhibitor p21 transcription through an androgen response element in its proximal promoter, while increased p21 has been linked with chemoresistance to the anti-microtubule agents in PCa. 29, 30 Therefore, we explored the potential linkage of p21 to the newly identified NEPCa-increased p38/Hsp27/AR signals. As shown in Figure 4a and Supplementary Figure S3 , co-culture with either NE1.3 or NCI-H660 cells resulted in increasing p21 in C4-2 and CWR22Rv1 cells. Knocking down AR with AR-shRNA partially reversed this NE1.3-cell-increased p21 upregulation in C4-2 and CWR22Rv1 (Figure 4b ). Importantly, adding p38 inhibitor could also partially reverse induction of p21 in C4-2 and CWR22Rv1 cells in response to NEPCa cells (Figure 4c) .
Interestingly, we found that p38/Hsp27/p21 signals are also activated in our Doc-resistant CWR22Rv1 cell line (Figure 4d ), suggesting that increased p38/Hsp2/p21 signaling is also associated with stable chemoresistance in PCa cells. Parathyroid hormone-related protein (PTHrP) secreted by NEPCa may be the pivotal molecule causing decreased chemo-sensitivity of PCa As the identified p38/Hsp27/AR/p21 signals were all in the neighboring PCa cells, we were interested to examine the signals upstream from NEPCa leading to the activation of the p38/Hsp27/ AR/p21 signals. Early studies suggested that NEPCa might secrete different kinds of cytokines and peptides, including bombesin, calcitonin, PTHrP, serotonin and vascular endothelial growth factor, to stimulate progression of its neighboring PCa. [9] [10] [11] 31, 32 We first compared the expression of some cytokines and peptides related to p38/MAPK signals between LNCaP and NE1.3 cells. [33] [34] [35] [36] [37] Only neurotensin and PTHrP showed a higher expression in NE1.3 cells (Figure 5a ). PTHrP is a key NEPCa-derived peptide-hormone that may have significant impacts on the neighboring PCa progression. 38 Indeed, Marin-Aguilar et al.
33
indicated that PTHrP might modulate the colon carcinoma cell proliferation via altering the p38/MAPK signals, and DaSilva et al.
10
also found that PTHrP might enhance PCa growth via stabilizing AR. Then, we investigated whether PTHrP is one of the key factors released from NEPCa to increase the neighboring PCa chemoresistance. We found that treatment of C4-2 and CWR22Rv1 cells with PTHrP (10 nM) for 24 h resulted in a decrease of cleaved PARP induced by treating with Doc, thus a reduced apoptotic induction (Figure 5b) . Similarly, TUNEL assays also resulted in reduced apoptosis upon PTHrP treatment in response to Doc treatment (Figure 5c ). Importantly, PTHrP also increased the phosphorylation of p38 and Hsp27 (Figure 5d ), as well as the p21 expression (Figure 5f ), in a time-dependent manner, with a maximum at 20 min. The expression of AR downstream genes, including PSA, TMPRSS2 and FKBP5, was also increased after treatment with PTHrP for 12 h (Figure 5e ). In addition, an interruption approach via lentiviral PTHrP knockdown also partially reversed the NEPCaincreased neighboring PCa chemoresistance (Figure 5g) .
Together, results from Figure 5 suggested that NEPCa may function through releasing PTHrP to increase the neighboring PCa chemoresistance.
NEPCa increased chemoresistance of neighboring PCa tissues in vivo Our results above indicated NEPCa-induced chemoresistance of neighboring PCa likely through p38/Hsp27/AR/p21 signaling pathway in vitro. We sought to determine whether in vivo NEPCa protected PCa from Doc-induced apoptosis. To do so, castrated nude mice were subcutaneously xenografted on left and right flanks either both with CWR22Rv1 cells or with CWR22Rv1 and NE1.3 cells in the two separate locations as it has been shown that NEPCa-released factors can circulate in the vasculature to reach the other side of the mouse. 39 After xenograft, when tumors grew to about 0.2 cm 3 , mice were randomized for intraperitoneal Doc administration at 30 mg/kg every 5 days for three treatments or vehicle treatments. The tumor volumes were measured by caliper every 5 days. Mice were killed 3 days after the last Doc administration. The results (Figures 6a and b) showed that after Doc administration, in mice bearing CWR22Rv1 tumors alone, tumor volumes/sizes decreased by about 67% compared with those with vehicle administration. In contrast, in mice bearing the CWR22Rv1 and NE1.3 tumors, the tumor volumes decreased by about 38% compared with those with vehicle administration. After Doc administration, CWR22Rv1 tumor volumes were 1.9-fold larger in mice bearing CWR22Rv1 and NE1.3 tumors than those in mice bearing CWR22Rv1 tumors alone.
These findings suggested that NEPCa increased Doc resistance of PCa tissues. Consistently, after Doc administration, mice bearing CWR22Rv1 and NE1.3 tumors showed an increased tumor weight when compared with those bearing CWR22Rv1 tumors alone (Figure 6c) .
To assess the role of NEPCa-induced chemoresistance of neighboring PCa tissues, we detected the expression of molecules that were examined in vitro through immunohistochemistry such as PSA, phospho-p38, phospho-Hsp27 and p21 in the xenograft tumors, and results were consistent with the findings in vitro, suggesting that molecular mechanisms that we discovered likely also functioned in vivo (Figure 6d ).
DISCUSSION
Overcoming Doc resistance has been a challenge since Doc was first established as a front-line therapy for metastatic CRPC. It has been found that some molecules are involved in Doc resistance. [40] [41] [42] However, there was no report indicating that NEPCa, as a component of the PCa tumors, have an important role in Doc resistance. In this study, we first demonstrated that NEPCa can protect neighboring PCa cells from Doc-induced apoptosis and increase the Doc resistance of their neighboring PCa cells. And our work may provide a potential method to conquer Doc resistance.
Prostatic NE cells are present in all PCa tumors, and are positively correlated with the cancer progression. As normal prostatic NE cells do not divide, there is strong evidence suggesting that transdifferentiation from prostate epithelial cells is the source of these NEPCa cells. And this transdifferentiation can be influenced by a variety of means such as androgen ablation, 43 hypoxia 44 and a particular tumor microenvironment. 45 The significance of NEPCa has been regarded as not only a sign for PCa progression, but also an inducer of growth and survival for the neighboring PCa by secreting a variety of cytokines and peptides. [9] [10] [11] 31, 32 For example, NEPCa secrete several neuropeptides, including bombesin, which can act as a mitogen in PCa tumors via activation of the transcription factor Elk-1 and the immediate early gene c-fos. 46 Certain receptors for serotonin may be overexpressed in PCa cells, particularly in high grade tumors, further supporting the hypothesis that NE products may promote androgen-independence of PCa through a paracrine mechanism. 47 Bombesin and calcitonin prevent apoptosis of PCa cells in vitro. 48, 49 Neuroendocrine differentiation may promote neovascularization of PCa as NEPCa are the major producers of vascular endothelial growth factor. 50 In addition, it was seen that contralateral implantation of NEPCa with androgen-sensitive PCa cells resulted in the latter xenograft being resistant to ADT, thus the development of CRPC. 39 All these data support the notion that human PCa is heterogeneous in nature, not just for multi-clonal origin for cancer initiation, but also in terms of the tumor microenvironment being composed of multiple kinds of cells helping each other in the tumor ecosystem.
In the present work, we found that NEPCa can result in the activation of p38/MAPK and Hsp27, which have a significant role in NEPCa-induced chemoresistance of PCa. P38/MAPK is a wellknown sensor of stress stimuli, such as cytokines, irradiation and heat shock, and is involved in cell differentiation, apoptosis and autophagy. [51] [52] [53] P38/MAPK has been involved in the progression of CRPC and accumulating evidence implicated an important role of p38/MAPK in activating AR via Hsp27 independent of androgen.
27 Hsp27, also known as heat shock protein beta-1 (HspB1), is highly expressed in CRPC. Clinical samples indicated that Hsp27 expression was significantly associated with PCa prognosis, and its overexpression confers resistance to androgen ablation and chemotherapy. 21, 22 Previous studies have shown that AR stability, nuclear shuttling and transactivation are all related to Hsp27. 27 For example, Razandi et al. 54 found that Hsp27 is required for sex steroid receptor (for example, AR) trafficking, which leads to kinase activation and DNA synthesis. In another study, the AR cofactor, hic-5/ARA55, was also found able to bind to Hsp27 and may also be involved in the upregulation of AR activity by Hsp27. 55 Recently, in a multicenter phase II clinical trial for CRPC, OGX-427, an antisense oligo of Hsp27, was found to possibly synergistically enhance Hsp90 efficacy through suppression of cell growth and induction of apoptosis accompanied by decreased expression of AR, PSA, and induction of endoplasmic reticulum stress. 56 Here, we showed that p38/MAPK-activated Hsp27 facilitated AR translocation to the nuclei. Targeting Hsp27 with OGX-427 may be a potential therapy to suppress NEPCainduced chemoresistance of PCa. We also showed p44/p42/MAPK in PCa cells could be activated by NEPCa NE1.3 cells and some studies also indicated that p44/p42/MAPK participated in chemoresistance of pancreatic cancer, non-Hodgkin's lymphoma B cells and PCa. [57] [58] [59] The roles of p44/p42/MAPK in NEPCa-induced docetaxel resistance of neighboring PCa need further exploration.
AR signaling has critical roles for PCa initiation and progression. 24 Activation of AR by androgen enhances LNCaP cell survival in the presence of cytotoxic stress. 26 Some studies also indicated interrupting microtubule-dependent trafficking of AR to the nucleus might be one of the potential mechanism of the Doc effect. 60 And recent data also suggested that enhanced AR activity, particularly expression of AR variants, is correlated with resistance to Doc. 41 Clinical data also showed that the cytoplasmic AR in circulating tumor might be associated with patients' responses to Doc. Consistent with this, clinical studies also found that ADT-naive metastatic PCa patients have enhanced survival if the initial ADT was coupled with Doc treatment, supporting the notion that increased AR activity reduces the efficacy of Doc or enhances Doc resistance. 61 Our studies strengthen the notion that enhanced AR activity is tightly connected with resistance to the Doc resistance induced by NEPCa cells.
Recently, Cerasuolo et al. 62 found neuroendocrine transdifferentiation in PCa cell populations, achievable under permanent androgen deprivation conditions, could influence the progression to androgen independence by providing an androgen-like substance from an increased level of cholesterol for the growth of androgen-dependent PCa cells. However, it remains to be determined that this increased cholesterol turns into an increased level of testosterone in this culture condition. On the other hand, it has been demonstrated that growth factors like insulin-like growth factor 1, epidermal growth factor and interleukin-6 could also behave as androgen-like agents by promoting AR phosphorylation and activation. [63] [64] [65] Here, we also proved that NEPCa activated AR in neighboring PCa cells indirectly via the p38/MAPK signal (Figure 3c ) with NE1.3 cells that were derived from permanent androgen deprivation as well as the patient-derived NEPCa cell line, NCI-H660 (Figure 2d ). In addition, we provided evidence that PTHrP from NEPCa cells can also impact AR function in neighboring PCa cells.
PTHrP is implicated in cellular calcium transport and smooth muscle cell contractility, and has crucial roles in cell proliferation and differentiation, especially for endochondral bone formation. PTHrP has also been connected with benign diseases, such as osteoporosis and osteoarthritis, as well as malignancies including most cancers and cancer-associated hypercalcemia. PTHrP is one of the wellknown NEPCa-derived peptides critical for tumor initiation, growth and metastasis. 38 Previous studies showed that PTHrP promoted epithelial-to-mesenchymal transition that is closely connected with metastasis and stemness in PCa. 66 It has also been shown that PTHrP enhanced PCa growth via both stabilizing AR and driving a CD11b+Gr1+ cell-mediated positive feedback loop. 10, 38 Particularly, it has been associated with skeletal metastases in the late stages of PCa, which frequently resulted in pathological fractures, bone pain and spinal cord compression. 67 Our studies indicated a role of PTHrP in protecting PCa from Doc-induced apoptosis, extending its long list of functions in the process of PCa progression, suggesting that it is an important target for the treatment of PCa.
In conclusion, NEPCa development and chemotherapy resistance are frequent occurrences in late stages of PCa. We found that NEPCa could secrete PTHrP to alter the p38/MAPK/Hsp27 signals in their neighboring PCa that resulted in increased AR activity via promoting AR nuclear translocation with a consequent increase of p21 that is linked with an increase of Doc resistance (Figure 7 ). These studies provide foundations to use small molecules targeting this newly identified p38/Hsp27/AR/p21 signaling pathway to restore sensitivity to Doc to better suppress PCa progression.
MATERIALS AND METHODS
Cell lines
The CWR22Rv1, DU145 and NCI-H660 cell lines were purchased from the American Type Culture Collection. We stably transfected human PCa PC3 cells with AR cDNA and named this cell line as PC3-AR9. 68 CWR22Rv1, DU145 and PC3-AR9 cells were cultured in RPMI 1640 with 10% fetal bovine serum, penicillin (25 units/ml) and streptomycin (25 g/ml). Doc-resistant clone, CWR22Rv1-Doc-R was selected by culturing cells with Doc in a dose-escalation manner. After sensitive clones were no longer present and surviving cells repopulated the dish, the concentration of Doc was increased gradually. CWR22Rv1-Doc-R cells were further exposed to 5 nM Doc. NCI-H660 cells were maintained in HITES media supplemented with 5% fetal bovine serum. The C4-2 cell line was a gift from Dr Jer-Tsong Hsieh (Southwestern Medical Center) and grown in RPMI 1640 media as above. The NE1.3 cells were a gift from Dr Lin Ming-Fong (University of Nebraska Medical Center) and were maintained in an SR media (Phenol Red-free RPMI 1640 supplemented with 5% charcoal/dextran-treated, heatinactivated fetal bovine serum, 1% glutamine and 0.5% gentamicin). All cell lines were cultured in a 5% (v/v) CO 2 humidified incubator at 37 ℃. Both C4-2 and CWR22Rv1 cells did not show NE differentiation in SR media for 72 h.
Reagents and materials GAPDH (6c5) and AR (N-20) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Phospho-p38 (Thr180/Tyr182) antibody was from Cell Signaling Technology (Danvers, MA, USA). AR antibody for intraperitoneal was from Millipore (Billerica, MA, USA). The p38 and PhosphoHsp27 (ser78) antibody were purchased from One World Lab (San Diego, CA, USA). Anti-mouse/rabbit second antibody for Western Blot was from Invitrogen (Carlsbad, CA, USA). The p38 inhibitor, SB203580, was from Apexbio (Houston, TX, USA). Doc was from Fisher Scientific (Waltham, MA, USA).
Cell proliferation assay
Cells were seeded in 48-well plates (2 × 10 3 cells/200 μl media per well) and incubated overnight for attachment. Then, they were treated with indicated doses of drugs in normal media for 24 or 48 h. After treatment, the media was replaced with MTT (0.5 mg/ml) at 37 ℃ for 45 min. After removal of media, the blue crystals were dissolved with 200 μl dimethyl sulfoxide per well, and absorbance at 570 nm was measured. 
Luciferase reporter assays
Cells were plated in 24-well plates and transfected with androgen response element-luciferase pGL3 and pRL-TK-luciferase plasmid using Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions. After indicated treatments, cells were lysed and the luciferase activity was detected by the Dual-luciferase Assay (Promega, Madison, WI, USA) and pRL-TK-luciferase was used as the internal control. Each sample was normalized by pRL-TK-luciferase activity, and data were presented as mean ± s.d. from at least three independent experiments.
Lentivirus package and transfection
The pLVTHM-shPTHrP or pLKO.1-shAR, the psAX2 packaging plasmid and pMD2G envelope plasmid were transfected into 293 T cells using the standard calcium chloride transfection method for 48 h to get the lentivirus soup. The lentivirus soup were collected and concentrated by density gradient centrifugation, and then frozen at − 80 ℃ for later use. The pSuperior-ARsiRNA targeting human AR mRNA sequence is 5′-G TGGCCGCAGCAAGGGGCTG-3′, the pSuperior-PTHrPsiRNA targeting human PTHrP mRNA sequence is 5′-GCTCACAGATTGAGGTAATAA-3′.
RNA extraction and quantitative real-time PCR analysis
Total RNAs were isolated using Trizol reagent (Invitrogen) and 1 μg of total RNA was subjected to reverse transcription using Superscript III transcriptase (Invitrogen). Quantitative real-time PCR (qRT-PCR) was conducted using a Bio-Rad (Hercules, CA, USA) CFX96 system with SYBR green to determine the mRNA expression level of a gene of interest. Expression levels were normalized to the expression of GAPDH RNA.
Western blot analysis
The expressions of specific genes were determined by the western blot according to a previous study. 69 Briefly, cells were lysed in RIPA buffer and proteins (20 μg) were separated on 8-10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel and then transferred onto polyvinylidene fluoride membranes (Millipore). After blocking membranes, they were incubated with appropriate dilutions (1:1000) of specific primary antibodies, the blots were incubated with horseradish peroxidaseconjugated secondary antibodies and visualized using ECL system (Thermo Fisher Scientific, Waltham, MA, USA).
In vivo subcutaneous implantation and docetaxel administration studies
Six-to eight-week-old male nude mice were castrated and used to create the animal model. CWR22Rv1 cells (1 × 10 6 suspended in 200 μl Matrigel) were injected subcutaneously in the right flank region of all the 28 mice. In the control group, CWR22Rv1 cells (1 × 10 6 suspended in 200 μl Matrigel) were also injected subcutaneously in the left flank region of 14 mice (CWR22Rv1-CWR22Rv1), while NE1.3 cells (1 × 10 6 suspended in 200 μl Matrigel) were injected into the left flank of the other 14 mice (CWR22Rv1-NE1.3). After xenograft tumors grew to about 0.2 cm 3 , seven of the CWR22Rv1-CWR22Rv1 mice and seven of the CWR22Rv1-NE1.3 mice were randomized to intraperitoneal Doc administration at 30 mg/kg every 5 days for three treatments and the seven remaining mice of each group were treated with vehicle. The mice were monitored and tumor volumes were measured by caliper (0.5236 × length × width) every 5 days. Mice were killed 3 days after the last Doc administration, and subcutaneous tumors were harvested for immunohistochemistry studies. All the animal experiments were performed in accordance with the guidelines of the University of Rochester Medical Center Animal Care and Use Committee for animal experiments.
Immunohistochemistry
Prostate tumor xenografts were fixed in 10% (v/v) formaldehyde in phosphate-buffered saline, embedded in paraffin and cut into 5-μm sections. Prostate cancer sections were deparaffinized in xylene solution and rehydrated using gradient ethanol concentrations. Antigen retrieval were preformed using EDTA at 98°C for 10 min. Then, slides were incubated with H 2 O 2 to block the endogenous peroxidase and incubated with the primary antibody at 4 ℃ overnight. After rinsing with Trisbuffered saline, the slides were incubated for 1 h with biotin-conjugated secondary antibody, washed, and then incubated with enzyme conjugate horseradish peroxidase-streptavidin. Freshly prepared DAB (Zymed, South San Francisco, CA, USA) was used as substrate to detect horseradish peroxidase. Finally, slides were counter-stained with hematoxylin and mounted with aqueous mounting media. Positive cells were calculated as the number of immunopositive cells × 100% divided by total number of cells/field in 10 random fields at × 400 magnification.
Statistics
All statistical analyses were carried out with SPSS 19.0 (SPSS Inc, Chicago, IL, USA). The data values were presented as the mean ± s.d. Differences in mean values between two groups were analyzed by two-tailed Student's t test and the mean values of more than two groups were compared with one way analysis of variance. P ⩽ 0.05 was considered statistically significant.
